论文部分内容阅读
目的 探讨 2型糖尿病患者血浆纤溶酶原激活物抑制物 1(PAI 1)水平与血管病变的关系。方法 采用酶联免疫吸附法 (ELISA)测定了 138例糖尿病患者 (无临床并发症 35例、并发症 10 3例 )和 31例健康体检者血浆PAI 1水平 ,同时将血浆PAI 1水平与血糖、血脂、胰岛素、体重和年龄等指标进行了相关分析。结果 138例糖尿病患者血浆PAI 1总体水平明显高于健康对照组 (P <0 0 1) ,且并发症组患者血浆PAI 1水平明显高于无临床并发症组 (P <0 0 1)。血浆PAI 1水平与血糖、血脂、胰岛素、体重等因素有关与患者年龄无关。结论 2型糖尿病患者血浆PAI 1水平显著增高 ,尤其是伴有血管病变的患者 ,PAI 1活性增高与糖尿病血管病变的发生、发展有关。
Objective To investigate the relationship between plasma plasminogen activator inhibitor 1 (PAI 1) and vascular diseases in type 2 diabetic patients. Methods Plasma PAI 1 levels were measured in 138 diabetic patients (35 without clinical complications and 103 with complications) and 31 healthy controls by enzyme-linked immunosorbent assay (ELISA). Plasma PAI 1 levels were also correlated with plasma glucose, Lipids, insulin, body weight and age were analyzed. Results The plasma levels of PAI-1 in 138 diabetic patients were significantly higher than those in healthy controls (P <0.01), and PAI1 levels in patients with complications were significantly higher than those without clinical complications (P <0.01). Plasma PAI 1 levels and blood glucose, blood lipids, insulin, body weight and other factors have nothing to do with the age of patients. Conclusion Plasma PAI 1 levels are significantly elevated in patients with type 2 diabetes mellitus, especially in patients with vascular lesions. The increased activity of PAI 1 is associated with the occurrence and development of diabetic vascular disease.